Want to join the conversation?
$BAX's sales in the biopharma solutions and other category, which is its partnering business, totaled $106MM, declining 19% on a reported basis or 12% on a constant currency basis. This decline is driven by a large customers choosing to self manufacture products that were previously contract manufactured by $BAX.
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?